Prolarix: Phase I data

In a dose-escalation, U.K. Phase I trial in 29 patients, Prolarix was well tolerated. The maximum tolerated dose was 26.6 mg/m 2. One patient with ocular melanoma had stable disease for >4 months. Dat...